The instruction for medical use of Groprinosin® medicine the Trade name of Groprinosin® the International unlicensed name Is not present the Dosage form of the Tablet, 500 mg Structure One tablet contains active agent - inosine pranobex 500 mg, excipients: potato starch, K-25 povidone, magnesium stearate the Description of the Tablet of an oval form, with a biconvex surface, from white till cream color, with risky for division on one party, 17 mm long and 7 mm wide. Pharmacotherapeutic group Antiviral drugs of direct action. Antiviral drugs other. Pranobex Kod ATH J05AX05 Pharmakologicheskiye inosine Pharmacokinetics Absorption properties: at intake, inosine pranobex is quickly and completely soaked up from digestive tract, the bioavailability of drug is about 90%. Distribution: the maximum concentration of inosine in plasma after intake, is reached in 1 hour, pharmacological action is shown approximately in 30 min. and keeps till 6 o'clock. Biotransformation and elimination: Inosine is metabolized on the cycle typical for purine nucleosides with formation of uric acid, other components are removed by kidneys in the form of the glucuronic and oxidized derivatives and also in not changed look. Cumulation in an organism is not revealed. Full removal of drug and its metabolites comes in 48 hours. The pharmacodynamics Active agent of the drug Groprinosin® - inosine pranobex shows direct antiviral and immunomodulatory action. Direct antiviral action is caused by linking with ribosomes of the cells affected with a virus that slows down synthesis virus i-RNK (disturbance of a transcription and broadcasting) and leads to oppression of RNA replication and DNA-genomic viruses, the mediated action is explained by induction of an interferonoobrazovaniye. The immunomodulatory effect is caused by influence on T lymphocytes (activation of synthesis of cytokines) and increase in phagocytal activity of macrophages. Under the influence of drug the differentiation pre-T-limfotsitov amplifies, the proliferation of T induced by mitogens is stimulated - and V-lymphocytes, their ability to synthesis of lymphokines increases functional aktivnostt-lymphocytes, including, the ratio between subpopulations T-helperov and T-suppressors is normalized. Гроприносин® considerably strengthens products of interleukin-2 lymphocytes and promotes an expression of receptors for this interleukin on lymphoid cells. Stimulates activity of natural killers (NK cells) at healthy people, stimulates activity of macrophages to phagocytosis, processing and the presentation of antigen that promotes increase in antibody producers in an organism from the first days of treatment. Stimulates also interleukin-1 synthesis, a mikrobitsidnost, an expression of membrane receptors and ability to react to lymphokines and chemotactic factors. In a herpes infection the development of specific antiherpetic antibodies accelerates, clinical manifestations and frequency of a recurrence decrease. Indications - an additional method of treatment at persons with the weakened immunity and recurrent upper respiratory tract infections. A route of administration and doses Only for intake. For simplification of reception of a tablet it is possible to crush and dissolve in a small amount of water. The dose is defined depending on the body weight of the patient and disease severity. The daily dose has to be divided into equal parts for reception several times a day. Duration of treatment is, as a rule, 5-14 days. Administration of drug should be continued within 1-2 days after reduction of expressiveness of symptoms. At adult patients, including at people of advanced age the recommended daily dose makes 50 mg/kg of body weight, i.e. from 6 to 8 tablets or on 2 tablets 3-4 times a day. The maximum dose makes 4 g a day. At children 6 years are more senior the daily dose makes 50 mg/kg of body weight appointed in stages. Side effects Often (≥1/100 to & lt, 1/10) - disturbances from nervous system: a headache, dizziness, fatigue, an indisposition - disturbances from digestive system: a loss of appetite, nausea, vomiting, pains in epigastric area - disturbances from skin and hypodermic cellulose: an itching, rash - disturbances from the musculoskeletal system and connective tissue: an arthralgia - disturbances from a gepatobiliarny system: increase in activity of transaminases, alkaline phosphatase or increase in content of the blood urea nitrogen (BUN) Infrequently (≥1/1,000 to & lt, 1/100) - disturbances from nervous system: nervousness, drowsiness or insomnia - disturbances from digestive system: diarrhea, a constipation - disturbances from kidneys and urinary tract: a polyuria (increase in volume of the emitted urine) - allergic reactions: spotty and papular rash, a small tortoiseshell, a Quincke's disease of the Contraindication - hypersensitivity to any component of drug - gout and also patients from the uric acid increased by concentration in blood and in urine - an urolithiasis - pregnancy and the period of a lactation (due to the lack of experience of use) - children's age up to 6 years Medicinal interactions of Groprinosin® it is necessary to apply with care at the patients who are at the same time receiving xanthineoxidase inhibitors (for example, Allopyrinolum), the drugs increasing discharge of uric acid with urine including diuretics as thiazide (for example, a hydrochlorothiazide, Chlortalidonum, indapamid), and loopback (furosemide, torasemid, Acidum etacrynicum).Гроприносин® it is not necessary to apply in time and right after the therapy termination by immunosuppressors as their simultaneous use can affect therapeutic effect of the drug Groprinosin® by change of its pharmacokinetics. At simultaneous use of the drug Groprinosin® and azidothymidine the formation of nucleotides due to strengthening of effect of azidothymidine, for example, owing to increase in bioavailability of azidothymidine and increase in intracellular phosphorylation in monocytes increases. Temporary increase in concentration of uric acid in blood serum and urine, as a rule, within the normal range (0.18-0.42 mmol/l), especially can cause the special instructions Groprinosin® in men and elderly people of both sexes. Increase in concentration of uric acid is caused by participation of inosine in its education, but not connected with change of the main functions of enzyme or renal clearance. Therefore Groprinosin® should be applied with care at patients with a renal failure. At these patients it is necessary to control carefully the level of uric acid during treatment. At long-term treatment by the drug Groprinosin® (3 months and longer) at each patient it is regularly necessary to control concentration of uric acid in blood serum and urine, indicators of the general blood test, function of a liver and kidneys (activity of transaminases, creatinine level). Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms did not study Influence of drug on speed of response at control of vehicles or other mechanisms. Considering a pharmacodynamics of inosine of a pranobex, it is improbable that this medicine affects ability of driving and use of mechanisms. Overdose any case of overdose of Groprinosina® is not registered. Symptoms: in case of overdose the increase in concentration of uric acid in blood serum and in urine is observed. Treatment: gastric lavage, symptomatic treatment. The form of release and packing On 10 tablets place in blister strip packaging from a film of PVH/PE/PVDH and aluminum foil. On 2 or 5 blister strip packagings together with the instruction for medical use in the state and Russian languages put in a cardboard pack. To Store storage conditions at a temperature not over 25 of 0C. To store out of children's reach! 3 years not to use a period of storage after the expiry date specified on packing. Prescription status Without prescription the Name and the country of the LLC Gideon Richter Polsha manufacturing organization, Poland the Name and the country of the owner of the registration certificate of JSC Gideon Richter, Hungary the Name and the country of the LLC Gideon Richter Polsha organization packer, Poland the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products:
To Develop representative office of JSC Gideon Richter in RK
To Develop representative office of JSC Gideon Richter in RK
Related Products
